The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.
The pharmaceutical industry faces mounting challenges in drug discovery, where exploring a chemical space exceeding 10 60 possible compounds remains computationally prohibitive. Traditional in-silico screening approaches struggle to capture the quantum mechanical interactions that determine molecular behavior. To overcome these limitations, this study introduces a hybrid quantum–classical machine learning framework that uniquely integrates molecular graph theory with quantum-enhanced learning for accelerated drug discovery. Using the QM9 benchmark dataset containing 133,885 molecules of low-to-medium structural complexity, we extract Laplacian eigenvalue spectra as topological descriptors that preserve both connectivity and electronic information. These features are jointly processed by Random Forest (RF), Support Vector Machine (SVM), and a Variational Quantum Classifier (VQC) in a weighted ensemble architecture designed for balanced generalization. The Quantum Graph Neural Network (QGNN) component achieves 97.5% accuracy, while the hybrid ensemble attains 100.0% accuracy, confirming strong predictive reliability. Although quantum training requires roughly 3.2× longer computation, it captures high-dimensional correlations that classical methods overlook. Overall, the proposed framework bridges the gap between theoretical quantum computing and practical pharmaceutical modeling, providing a scalable, physics-inspired pathway toward intelligent molecular screening and next-generation drug discovery systems.
Abstract Quantum computing has emerged as a powerful tool for modeling molecular systems with high accuracy, accelerating the search for novel therapeutic targets. In this study, we present a two-stage hybrid workflow that combines a Quantum Graph Neural Network with a Variational Quantum Eigensolver to identify potent serine neutralizers in the QM9 dataset. In the first stage, an advanced quantum graph neural network architecture incorporating attention layers, self-distillation, and an adaptive learning-rate schedule is trained to predict ionization potentials and binding free energies. Across five independent random-seed trials, our adaptive-thresholded QGNN–VQE pipeline achieves an average R2 R 2 of 0.990±0.008 0.990 ± 0.008 and a mean absolute error of 0.034±0.001 0.034 ± 0.001 eV ( ≈0.79±0.03 ≈ 0.79 ± 0.03 kcal/mol) on the QM9 validation set, demonstrating robust, chemical-accuracy-level predictions. Building on these high-precision predictions, the second stage employs a QAOA-inspired hybrid ranking scheme that merges quantum graph neural network outputs, feature-space similarity (via and cosine similarity), and variational quantum eigensolver-derived energy stability. This α α -weighted ( α=0.95 α = 0.95 ) scoring framework is applied to over 133,000 molecules, efficiently parsed in parallel. The final ranked list is validated through an improved bijection test, featuring an adaptive similarity threshold to ensure both structural and functional robustness. The top-scoring candidate identified by our pipeline is 5,6,7-tetrahydro-4 H-pyrazolo[4,3-c]pyridin-4-one, highlighting the efficacy of quantum-enhanced modeling in pinpointing complex pharmacological targets. These findings underscore the transformative potential of hybrid quantum-classical workflows in drug discovery, offering a flexible blueprint for advanced screening of other critical biomolecular interactions in the rapidly expanding field of quantum biology. GraphicAbstract VQE for Serine Neutralization
Recent advances in quantum machine learning (QML) have opened new pathways for accelerating early-stage drug discovery through molecular representation in Hilbert space [1]–[3]. In this work, we present a hybrid quantum–classical framework that integrates quantum kernel estimation and variational quantum neural networks (QNNs) for ligand–target binding prediction [4], [5].A synthetic dataset reflecting the statistical behavior of the BindingDB database [6] was constructed to evaluate quantum descriptors and kernel performance under controlled conditions. The proposed quantum feature maps translate seven key molecular descriptors—molecular weight (MW), logP, hydrogen bond donors (HBD), acceptors (HBA), rotatable bonds (RB), aromatic rings (AR), and topological polar surface area (TPSA)—into entangled qubit states [7], [8].Comparative analyses with classical baselines (SVR, Random Forest, and deep neural networks) revealed that quantum embeddings achieve competitive predictive accuracy (RMSE ≈ 0.06) with improved stability under bootstrap resampling [9]. Quantum kernel alignment and sensitivity studies demonstrated that aromaticity and polarity jointly determine the representational power of QML models [10].Beyond performance, we emphasize Explainable Quantum Pharmacology (EQP)—a paradigm in which interpretability, reproducibility, and physicochemical causality are as essential as accuracy [11].Our findings establish a reproducible, interpretable, and computationally efficient foundation for hybrid QML pipelines in molecular modeling, paving the way for next-generation AI-driven drug discovery.
Finding drug-like molecules is a time- and money-consuming task that requires virtual screening techniques capable of accurately representing non-linear intermolecular relationships. Classical ML models usually consider molecular graphs or SMILES sequences, but cannot jointly exploit both structural and sequential information, let alone simultaneously. Of greater importance, numerous deep learning methods are hindered by poor generalisation, black-box predictions, and inadequate interpretability, reducing their feasibility for application in real-life drug discovery pipelines. In this paper, we present QDrugDiscoverAI, a hybrid quantum–classical deep learning framework for predicting molecular properties and optimising molecules to overcome these challenges. We present a framework for multimodal molecular representation learning that combines graph attention networks and transformer-based sequence encoders with variational quantum circuits to increase expressive capacity within a single architecture. It implements a dual-stream representation-learning mechanism with a multimodal feature fusion layer. It includes an explainability module that uses attention weights and SHAP values to identify substructures that contribute to model predictions and enhance interpretability. Moreover, QDrugDiscoverAI also includes a quantum–assisted reinforcement-learning module for a molecule-optimisation workflow, enabling more efficient exploration of the chemical design space while leveraging the controllability of quantum simulation. The experiments on three benchmark datasets, i.e., Lipophilicity, HIV, and BBBP, show improvements of 12.4%, 9.6%, and 11.1% in accuracy, AUC, and F1-score, respectively, over the matched classical and unimodal baselines. Quantitative evaluation of quantum components and fusion strategies is also conducted through ablation studies to demonstrate their roles further. In summary, the framework proposed serves as a systematic integration of interpretable hybrid learning, showing one way it could be organised to become increasingly efficient, and demonstrating the advantage of using quantum-simulated components to enhance classical deep learning models for exploration and predictive performance in drug discovery workflows. The implementation code and supporting scripts for the proposed QDrugDiscoverAI framework are publicly available at: https://github.com/Sripada-RamaSree/QuantumDrugAI
The exorbitant costs, protracted timelines, and elevated attrition rates associated with traditional drug-discovery pipelines underscore the pressing necessity for computational frameworks that can elucidate biomolecular interactions with quantum-level precision and practical scalability. This study introduces a Hybrid Quantum Classical (HQC) framework that combines quantum variational algorithms, classical molecular dynamics, and quantum-assisted machine-learning optimization into a single drug-screening workflow. It builds on the basic idea of Quantum Molecular Simulation (QMS). In the suggested design, quantum processors are used to selectively fix high-fidelity electronic interactions in reactive binding sites, while classical engines model the large-scale conformational dynamics of biomolecular environments. An adaptive quantum-machine-learning layer speeds up convergence even more by learning how structure and energy are related from quantum-refined descriptors. Benchmark tests against oncogenic targets like EGFR, BCR-ABL1, and p53 show that our method is up to 27% more accurate at converging binding energy and takes 4.3 times less time to compute than standard density-functional-theory and standalone QMS methods. The HQC framework makes quantum drug simulation possible for real-world drug discovery by reducing the limitations of current quantum hardware while keeping electronic-scale accuracy. This study demonstrates that hybrid quantum-classical modeling is a scalable and hardware-compatible approach for advancing next-generation computational drug design and precision therapeutics.
The growing public and private datasets focused on small molecules screened against biological targets or whole organisms 1 provides a wealth of drug discovery relevant data. Increasingly this is used to create machine learning models which can be used for enabling target-based design 2-4, predict on- or off-target effects and create scoring functions 5,6. This is matched by the availability of machine learning algorithms such as Support Vector Machines (SVM) and Deep Neural Networks (DNN) that are computationally expensive to perform on very large datasets and thousands of molecular descriptors. Quantum computer (QC) algorithms have been proposed to offer an approach to accelerate quantum machine learning over classical computer (CC) algorithms, however with significant limitations. In the case of cheminformatics, one of the challenges to overcome is the need for compression of large numbers of molecular descriptors for use on QC. Here we show how to achieve compression with datasets using hundreds of molecules (SARS-CoV-2) to hundreds of thousands (whole cell screening datasets for plague and M. tuberculosis) with SVM and data re-uploading classifier (a DNN equivalent algorithm) on a QC benchmarked against CC and hybrid approaches. This illustrates a quantum advantage for drug discovery to build upon in future.
Quantum machine learning (QML) has been demonstrated to have great potential in revolutionizing the process of drug discovery by dealing with the problem of high computational complexity of molecular simulations. Conventional computational techniques are not very effective in predicting the properties of molecules and pharmaceutical activity because the simulation of large molecules is too complex. This paper will discuss how QML algorithms can be used, specifically variational quantum circuits and quantum kernel methods, to improve the predictability of molecular properties and accelerate the process of drug discovery. To enhance the prediction accuracy, the research use quantum-enhanced feature extraction together with classical machine learning technologies. Research methodology is applied to datasets of molecular structure and biological activity in order to provide a more useful model to learn about how molecular features relate to biological outcomes using quantum machine learning models. These results suggest that it is 15 % more accurate in prediction and 20 % faster in computing high-dimensional molecular simulations compared to standard machine learning algorithms. The efficiency of the QML-based method is statistically proven with an accuracy 89%, precision 87%, and an F1-score of 0.91. The results point to the possible ability of QML to decrease the time and computational resources spent on the exploration of drug discovery, providing a new direction for the improvement of molecular property prediction. The study is a contribution to the emerging area of QML in pharmaceutical use and demonstrates that it can simplify drug discovery and enhance the accuracy with which predictions are made. The paper demonstrates that QML may produce a significant impact on the drug development process by simulating the molecular properties faster, more effectively, and more accurately.